I did some-learning
today. Dealing with acute transfusion reactions, and obtaining consent for
transfusion. All refresher rather than anything new… but valuable nonetheless.
This is (supposed to be) a reflective diary by a (not very) anonymous biomedical scientist who works somewhere in the south of England. One day this diary may well be submitted to the Health and Care Professions Council as evidence of ongoing continual professional development....
26 Nivember 2019 (Tuesday) - CPD Presentation
Over
lunchtime we had a couple of CPD presentations.
The first
was an overview of the history of blood transfusions, and the second was a
resume of the use of transfusion in patients with major hemorrhage.
Both were
interesting; both were valuable, and directly relevant to what I do.
Back in
the day I used to organise one of these sorts of thing every week. I miss
them... I wonder if there would be the enthusiasm for this nowadays. But then
again, it is up to the official Training Officer to sort that out. Not my place
to do this any more.
Do I miss
it... I miss the talks. I *don't* miss the aggro that goes with chivvying up
the volunteers (conscripts)
21 November 2019 (Thursday) - Transfusion News email
Revised
criteria for platelet transfusions, another step towards artificial blood, and yet
more praise for tranexamic acid… The Transfusion news email is rather good…
 November 20, 2019Globally, more than 60 million cases of traumatic brain injury occur annually, most of which are due to motor vehicle crashes and falls. Tranexamic acid (TXA), an antifibrinolytic drug which slows the breakdown of blood clots and prevents prolonged bleeding, has been shown to reduce bleeding and mortality in patients with [Read More] |
|||
 November 20, 2019 | BBGuy PodcastPlatelet transfusion decisions must Involve more than just the platelet count! Joe Sweeney explains how we can all make better choices. [Listen Now] |
|||
|
|||
 November 13, 2019Cost-effective, large-scale production of red blood cells (RBCs) would eliminate blood shortages and ensure antigen-compatible cells are available for alloimunized patients. RBCs have been cultured from cord blood cells, but the yield is low and cells produce [Read More] |
Subscribe to:
Posts (Atom)